HDAC inhibitors have also been shown to enhance the efficacy of JAK2 inhibitors in myeloproliferative disorders by downregulating JAK2 and JAK2 V617F through acetylation of the chaperone protein HSP90 [60]. The gene discussed is JAK2; the disease is myeloproliferative disorder.